One of most lethal forms of cancer, Pancreatic Ductal Adenocarcinoma (PADC), has been classed on wrong side of chemosensitivity scale- those varieties that are very resistant to chemotherapy. The prognosis for PADC diagnosed at a late stage is poor, with a 5-year survival of less than 10%. However, nanomedicine may actually help constitute a plausible avenue for improving effectiveness of PADC t
